Document 0520
 DOCN  M9480520
 TI    Hepatitis C virus (HCV) viremia in human immunodeficiency
       virus-seronegative and -seropositive patients with indeterminate HCV
       recombinant immunoblot assay.
 DT    9410
 AU    Marcellin P; Martinot-Peignoux M; Elias A; Branger M; Courtois F; Level
       R; Erlinger S; Benhamou JP; Service d'Hepatologie, INSERM U24, Hopital
       Beaujon, Clichy,; France.
 SO    J Infect Dis. 1994 Aug;170(2):433-5. Unique Identifier : AIDSLINE
       MED/94308614
 AB    Positivity of recombinant immunoblot assay (RIBA) for detection of
       antibodies to hepatitis C virus (anti-HCV) is usually associated with
       HCV viremia. The significance of an indeterminate RIBA result, defined
       by reactivity to only one HCV antigen, is unclear. Whether anti-human
       immunodeficiency virus (HIV)-negative or -positive subjects with an
       indeterminate RIBA have HCV viremia detectable by polymerase chain
       reaction was investigated. An indeterminate RIBA was found in 48 (15%)
       of 318 anti-HIV-negative and 38 (23%) of 167 anti-HIV-positive subjects
       (P < .05). Clinical stage was IV-C-1 or IV-C-2 in 82% of those
       anti-HIV-positive. HCV viremia was found more frequently in
       anti-HIV-positive (89%) than in anti-HIV-negative subjects (50%) with an
       indeterminate RIBA (P < .05). These results suggest an impaired anti-HCV
       response associated with HIV infection.
 DE    Alanine Aminotransferase/BLOOD  Antigens, Viral/IMMUNOLOGY
       Enzyme-Linked Immunosorbent Assay  Hepatitis Antibodies/BLOOD  Hepatitis
       C/*COMPLICATIONS  Hepatitis C Viruses/GENETICS/IMMUNOLOGY  Human  *HIV
       Seronegativity  HIV Seropositivity/*COMPLICATIONS  Immunoblotting
       Polymerase Chain Reaction  Recombinant Proteins/IMMUNOLOGY  RNA,
       Viral/BLOOD  Support, Non-U.S. Gov't  Viremia/*COMPLICATIONS  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).